{{noteTA
|G1=生命科学
|1=zh-cn:组蛋白;zh-tw:組織蛋白;
|2=zh-cn:脱乙酰酶;zh-tw:去乙醯酶;
}}{{medical}}
'''組織蛋白去乙醯酶抑制劑'''({{lang-en|HDAC inhibitor}}，簡寫'''HDI'''或'''HDAC抑制劑''')是一種透過抑制身體內[[組織蛋白去乙醯酶|組織蛋白去乙醯酶]]功能的藥物類別，亦存在於[[胎兒|胎兒]]及[[花椒|花椒]]內。現時有健康食品生產商建議透過進食[[花椒油|花椒油]]而達至[[防癌|防癌]]的功效。

現時醫學界有研究透過「組織蛋白去乙醯酶抑制劑」來治療[[癌症|癌症]]<ref>{{cite journal |author=Marks PA, Dokmanovic M |title=Histone deacetylase inhibitors: discovery and development as anticancer agents |journal=Expert opinion on investigational drugs |volume=14 |issue=12 |pages=1497-511 |year=2005 |pmid=16307490 |doi=10.1517/13543784.14.12.1497}}</ref>及[[神经退行性疾病|神经退行性疾病]](neurodegenerative diseases)。這些抑制劑的具體機制，例如有關的化合物如何達到有關的功效，到現在還未清楚。不過，有關文獻亦有提出可能的[[表觀遺傳學|表觀遺傳學]]途徑<ref>{{cite journal
  | author = Claude Monneret
  | title = Histone deacetylase inhibitors for epigenetic therapy of cancer
  | journal = Anticancer Drugs
  | volume = 18
  | pages = 363-70
  | date = April 2007}}
</ref> Richon et al.<ref name=Richon> Richon VM, Sandhoff TW, Rifkind RA, Marks PA. AUG 29 2000. "Histone deacetylase inhibitor selectively induces p21(WAF1) expression and gene-associated histone acetylation."  ''[[Proceedings_of_the_National_Academy_of_Sciences_of_the_United_States_of_America|Proceedings of the National Academy of Sciences of the United States of America]]'' 97(18):10014-10019. </ref>發現HDAC抑制劑可以透過引導[[p21|p21]] (WAF1)來調節[[p53|p53]]的[[腫瘤壓抑基因|腫瘤抑制]]功能<ref name=el-Deiry> el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. NOV 19 1993. "WAF1, a potential mediator of p53 tumor suppression."  ''[[Cell_(journal)|Cell]]'' 75(4):817-25. </ref>。對於 HDAC 抑制劑如何調控基因表達 ，目前已有比較大的進展。持續的研究 HDAC 抑制劑的調節基因機制，將快速促進新藥設計及生物標記的鑑定 <ref>{{Cite journal|title=Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells|url=http://online.liebertpub.com/doi/10.1089/ars.2014.5863|last=Chueh|first=Anderly C.|last2=Tse|first2=Janson W.T.|date=2014-02-10|journal=Antioxidants & Redox Signaling|issue=1|doi=10.1089/ars.2014.5863|volume=23|pages=66–84|issn=1523-0864|pmc=4492771|pmid=24512308|last3=Tögel|first3=Lars|last4=Mariadason|first4=John M.}}</ref>。<!--以下未譯：  HDACs are involved in the pathway by which the [[retinoblastoma_protein|retinoblastoma protein]] (pRb) suppresses [[cell_proliferation|cell proliferation]].  The pRb protein is part of a complex which attracts HDACs to the [[chromatin|chromatin]] so that it will deacetylate histones.<ref name=Brehm>Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. 1998 Retinoblastoma protein recruits histone deacetylase to repress transcription.
''[[Nature_(journal)|Nature]]'' 391(6667):597-601.</ref> HDAC1 negatively regulates the cardiovascular transcription factor Kruppel-like factor 5 through direct interaction.<ref name=Matsumura> Matsumura T, Suzuki T, Aizawa K, Munemasa Y, Muto S, Horikoshi M, Nagai R 2005 The deacetylase HDAC1 negatively regulates the cardiovascular transcription factor Kruppel-like factor 5 through direct interaction.''[[J_Bio_Chem(journal)J_Bio_Chem|J Bio Chem(journal)J Bio Chem]]'' 280(13):12123-9 </ref>
Estrogen is well-established as a mitogenic factor implicated in the tumorigenesis and progression of breast cancer via its binding to the estrogen receptor alpha (ERalpha). Recent data indicate that chromatin inactivation mediated by HDAC and DNA methylation is a critical component of ERalpha silencing in human breast cancer cells.<ref name=zhang> Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast.2005 [[Breast_Cancer_Res_Treat|Breast Cancer Res Treat]]Nov;94(1):11-6.</ref>

HDAC inhibitors are also associated with the inhibition of some gene promoters. This could be due to increased activity of other, negative-regulatory proteins, however.

Examples include [[SAHA|SAHA]], [[LAQ824|LAQ824]]/[[LBH589|LBH589]], [[CI994|CI994]], [[MS275|MS275]] and [[MGCD0103|MGCD0103]].<ref>{{cite journal |author=Beckers T, Burkhardt C, Wieland H, ''et al'' |title=Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group |journal=Int. J. Cancer |volume=121 |issue=5 |pages=1138-48 |year=2007 |pmid=17455259 |doi=10.1002/ijc.22751}}</ref>-->

== 參考 ==
{{Reflist|2}}

{{酶抑制}}

[[Category:组蛋白脱乙酰酶抑制剂|]]
[[Category:抗肿瘤药|Category:抗肿瘤药]]
[[Category:情绪稳定剂|Category:情绪稳定剂]]